Equity Profile

DNLI

Denali Therapeutics Inc.

Health CareBiotechnology$3.1B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

EPS

Earnings per share will indicate how well the company is managing its costs and progressing towards profitability.

N/A

Revenue Growth

While specific revenue estimates are not available, any signs of growth are crucial for investor confidence in the company's pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. With a market cap of $3 billion, the company operates in the health care sector, which is increasingly relevant as the population ages and the demand for effective treatments rises.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In Q1 2026, Denali reported an EPS of -$0.69, slightly better than the expected -$0.73. However, the stock fell by 3.43% the following day, reflecting ongoing investor concerns.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, given the company's history of losses and mixed performance in previous quarters.

Bull Case

If Denali can show improved EPS and any positive developments in its drug pipeline, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides no clear path to profitability, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in the pipeline?

Investors will be keen to understand if Denali is on track with its development timelines, which could impact future revenue potential.

How does management plan to address ongoing losses?

Any concrete plans for cost management or revenue generation will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Denali's potential for cost reduction and drug pipeline advancements, which could lead to a surprise in performance.

Supporting Evidence

Denali has a history of beating EPS estimates, which may not be fully priced in.

The options market is pricing a significant move, indicating that investors are expecting more volatility than usual.

Key Risk

If the company can demonstrate a clear path to reducing losses, it could shift investor sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus will be on the company's ability to manage costs while advancing its drug development efforts.

Bull Confirmed If

A reduction in EPS losses to below -$0.60 would indicate better cost management and operational efficiency.

Bear Confirmed If

If EPS losses exceed -$0.75, it would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations, history suggests the stock could rise by around 4.52%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity.

Miss

A miss could lead to a decline of approximately 2.88%, reflecting ongoing concerns about the company's path to profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for drug candidates in development.
2Any commentary on cost management strategies.
3Details on partnerships or collaborations that could enhance revenue.
4Insights into market conditions affecting the biotechnology sector.
5Management's outlook on future profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

EPS

Earnings per share will indicate how well the company is managing its costs and progressing towards profitability.

N/A

Revenue Growth

While specific revenue estimates are not available, any signs of growth are crucial for investor confidence in the company's pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In Q1 2026, Denali reported an EPS of -$0.69, slightly better than the expected -$0.73. However, the stock fell by 3.43% the following day, reflecting ongoing investor concerns.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, given the company's history of losses and mixed performance in previous quarters.

Bull Case

If Denali can show improved EPS and any positive developments in its drug pipeline, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides no clear path to profitability, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in the pipeline?

Investors will be keen to understand if Denali is on track with its development timelines, which could impact future revenue potential.

How does management plan to address ongoing losses?

Any concrete plans for cost management or revenue generation will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Denali's potential for cost reduction and drug pipeline advancements, which could lead to a surprise in performance.

Supporting Evidence

Denali has a history of beating EPS estimates, which may not be fully priced in.

The options market is pricing a significant move, indicating that investors are expecting more volatility than usual.

Key Risk

If the company can demonstrate a clear path to reducing losses, it could shift investor sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus will be on the company's ability to manage costs while advancing its drug development efforts.

Bull Confirmed If

A reduction in EPS losses to below -$0.60 would indicate better cost management and operational efficiency.

Bear Confirmed If

If EPS losses exceed -$0.75, it would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations, history suggests the stock could rise by around 4.52%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity.

Miss

A miss could lead to a decline of approximately 2.88%, reflecting ongoing concerns about the company's path to profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for drug candidates in development.
2Any commentary on cost management strategies.
3Details on partnerships or collaborations that could enhance revenue.
4Insights into market conditions affecting the biotechnology sector.
5Management's outlook on future profitability.